The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer

PURPOSE: In a phase III study of gemcitabine plus erlotinib for advanced pancreatic cancer conducted in Canada, the incidence of interstitial lung disease (ILD) was 3.5 %. However, the incidence of ILD was reported as high as 8.5 % in a Japanese phase II study. These results suggest the influence of...

詳細記述

保存先:
書誌詳細
出版年:Cancer Chemother Pharmacol
主要な著者: Nishimura, Meiko, Toyoda, Masanori, Takenaka, Kei, Imamura, Yoshinori, Chayahara, Naoko, Kiyota, Naomi, Mukohara, Toru, Kotake, Takeshi, Tsuji, Akihito, Saito, Kosuke, Saito, Yoshiro, Minami, Hironobu
フォーマット: Artigo
言語:Inglês
出版事項: Springer Berlin Heidelberg 2016
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4882349/
https://ncbi.nlm.nih.gov/pubmed/27100735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3026-6
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料